Skip to Content Facebook Feature Image

China's AS700 manned airship completes maiden low-altitude flight in plateau region

China

China

China

China's AS700 manned airship completes maiden low-altitude flight in plateau region

2025-09-29 19:48 Last Updated At:22:57

China's homegrown AS700 manned airship successfully completed its first flight over southwest China's Yunnan-Guizhou Plateau, comprehensively verifying the airship's stability and safety in low-altitude flight environments over plateau areas, said the Aviation Industry Corporation of China (AVIC), the country's leading plane maker, on Monday.

The airship flew at an altitude of 1,200 meters over the Yunnan-Guizhou Plateau. It boasts a maximum range of 700 kilometers and a maximum endurance of 10 hours. Leveraging its unique thrust vector control technology, it can achieve short takeoff and landing, and vertical takeoff and landing in simple sites with a diameter of just 150 meters.

According to the AVIC, the parameters and data on plateau flight performance and environmental adaptation obtained from this flight will further drive product improvements and iterations. This will also enable the airship to better adapt to diverse application scenarios and lay the foundation for expanding into more fields including emergency rescue and aerial monitoring, as well as developing customized flight support solutions.

The AVIC plans to further refine its application solutions for the southwestern region in China, with a particular focus on low-altitude tourism. This initiative is designed to position aviation equipment as a "new engine" for energizing the local low-altitude economy.

China's AS700 manned airship completes maiden low-altitude flight in plateau region

China's AS700 manned airship completes maiden low-altitude flight in plateau region

China on Sunday unveiled an updated version of its national medical insurance drug list and the inaugural edition of the commercial insurance innovative drug list, according to the National Healthcare Security Administration.

The updated national medical insurance drug list has added 114 drugs, among which 50 are innovative pharmaceuticals. It has incorporated certain medications that fill the gaps in basic medical insurance coverage, such as drugs for major diseases, rare diseases, and chronic conditions.

The commercial insurance innovative drug list included 19 drugs for the treatment of tumors, rare diseases, and Alzheimer's, among others.

The country's medical insurance authority has adjusted the list for eight years in a row, increasing the total number of medications to 3,253 and significantly improving coverage in key areas such as oncology, chronic diseases, mental illnesses, rare diseases, and pediatric medications.

China updates national medical insurance catalog, adds 114 new drugs

China updates national medical insurance catalog, adds 114 new drugs

Recommended Articles